Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 81

Sort by

Sort Order Select

Journal Articles

Risk prediction for clonal cytopenia: multicenter real-world evidence

Blood (2024) 144 (19): 2033–2044.

https://doi.org/10.1182/blood.2024024756

Published: 2024

Includes: Supplemental data

Journal Articles

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 4597.

https://doi.org/10.1182/blood-2024-206034

Published: 2024

Journal Articles

R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Guillermo Garcia-Manero, Yazan F Madanat, Mikkael A. Sekeres, Hetty E. Carraway, Mike Cusnir, James McCloskey, Kiran Naqvi, Gary J. Schiller, Lucy Yan, Toufigh Gordi, Lisa Rojkjaer, Lewis R. Silverman

Blood (2024) 144 (Supplement 1): 4595.

https://doi.org/10.1182/blood-2024-206096

Published: 2024

Journal Articles

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

Blood (2024) 144 (Supplement 1): 1845.

https://doi.org/10.1182/blood-2024-207474

Published: 2024

Journal Articles

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Blood (2024) 144 (Supplement 1): 2907.2.

https://doi.org/10.1182/blood-2024-210967

Published: 2024

Journal Articles

Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (m IDH1 ) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria

Yazan F Madanat, Amir T. Fathi, Guillermo Garcia-Manero, Gail J. Roboz, Justin M. Watts, Gabrielle T. Prince, Praneeth Baratam, Stephane De Botton, Anthony S. Stein, James M. Foran, Martha L. Arellano, David Sallman, Yuanye (Vickie) Zhang, Stephanie M. Kapsalis, Prapti A. Patel, Courtney D. DiNardo

Blood (2024) 144 (Supplement 1): 1841.

https://doi.org/10.1182/blood-2024-204862

Published: 2024

Journal Articles

Genetic Profiling and Survival Analysis of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

Blood (2024) 144 (Supplement 1): 6127.

https://doi.org/10.1182/blood-2024-199358

Published: 2024

Journal Articles

Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?

Tariq Kewan, Arda Durmaz, Waled Bahaj, Carmelo Gurnari, Olisaemeka Ogbue, Ahmad Kiwan, Hussein Awada, Hetty E. Carraway, Suresh Kumar Balasubramanian, Taha Bat, Yazan F Madanat, Valeria Visconte, Jaroslaw Maciejewski

Blood (2024) 144 (Supplement 1): 850.

https://doi.org/10.1182/blood-2024-207770

Published: 2024

Journal Articles

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Benjamin Rolles, Jan Philipp Bewersdorf, Tariq Kewan, Ondrej Blaha, Jessica M. Stempel, Luca Lanino, Najla H. Al Ali, Amy E. DeZern, Mikkael A. Sekeres, Geoffrey L. Uy, Hetty E. Carraway, Pinkal Desai, Elizabeth A. Griffiths, Eytan M. Stein, Andrew M. Brunner, Christine M. McMahon, Rory M. Shallis, Joshua F Zeidner, Michael R. Savona, Stacey M. Frumm, Shougat Barua, Namrata S. Chandhok, Constantine Logothetis, Aram Bidikian, Ted M. Getz, Gail J. Roboz, Eunice S. Wang, Amyah C. Harris, Maria L Amaya, Hayley Hawkins, Somedeb Ball, Justin Grenet, Zhuoer Xie, Yazan F Madanat, Yasmin Abaza, Talha Badar, Torsten Haferlach, Jaroslaw Maciejewski, David Sallman, Anoop K Enjeti, Kamal Al-Rabi, Khalid Halahleh, Devendra Hiwase, Maria Diez-Campelo, David Valcarcel, Claudia Haferlach, Lisa Pleyer, Ioannis Kotsianidis, Vassiliki Pappa, Valeria Santini, Angela Consagra, Aref Al-Kali, Seishi Ogawa, Yasuhito Nannya, Matteo Giovanni Della Porta, Rami S. Komrokji, Amer M. Zeidan, Maximilian Stahl

Blood (2024) 144 (Supplement 1): 664.

https://doi.org/10.1182/blood-2024-208034

Published: 2024

Journal Articles

Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)

Guillermo Garcia-Manero, James McCloskey, Bart L. Scott, Elizabeth A. Griffiths, Bonnie Kiner-Strachan, Andrew M. Brunner, Amer M. Zeidan, Elie Traer, Yazan F. Madanat, Janelle Meyer, Harry Erba, Praneeth Baratam, Uma Borate, Yuri Sano, Aram Oganesian, Lixia Zhu, Harold N. Keer, Michael R. Savona

Blood (2024) 144 (Supplement 1): 662.

https://doi.org/10.1182/blood-2024-203569

Published: 2024

Journal Articles

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Blood (2024) 144 (Supplement 1): 214.

https://doi.org/10.1182/blood-2024-198218

Published: 2024

Journal Articles

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Blood (2024) 144 (Supplement 1): 1564.

https://doi.org/10.1182/blood-2024-211261

Published: 2024

Journal Articles

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

Blood (2024) 144 (Supplement 1): 352.

https://doi.org/10.1182/blood-2024-203612

Published: 2024

Journal Articles

A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3 -Mutated Relapsed or Refractory Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 2883.4.

https://doi.org/10.1182/blood-2024-208822

Published: 2024

Journal Articles

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

Mikkael A. Sekeres, Valeria Santini, Amer M. Zeidan, Uwe Platzbecker, Rami S. Komrokji, Maria Diez-Campelo, Pierre Fenaux, Michael R. Savona, Yazan F. Madanat, David Valcarcel, Antoine Regnault, Kristin Creel, Nishan Sengupta, Souria Dougherty, Sheetal Shah, Libo Sun, Ying Wan, Shyamala Navada, Esther Natalie Oliva

Blood (2024) 144 (Supplement 1): 3210.

https://doi.org/10.1182/blood-2024-199636

Published: 2024

Journal Articles

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Mikkael A. Sekeres, Hetty E. Carraway, Richard M Stone, Yazan F Madanat, Rami S. Komrokji, Sangeetha Venugopal, Namrata S. Chandhok, Terrence Bradley, Justin Taylor, Anastasia Santiago, Alessia Zoso, Justin M. Watts, Amy E. DeZern

Blood (2024) 144 (Supplement 1): 1821.

https://doi.org/10.1182/blood-2024-203965

Published: 2024

Journal Articles

Bi-Allelic DDX41 Mutations Exert Stage Specific Effects on Hematopoiesis to Promote Disease

Benjamin Kroger, Yuanyuan Ji, Toby Thomas, Yazan F Madanat, Robert H. Collins, Valeria Visconte, Carmelo Gurnari, Jaroslaw Maciejewski, Stephen Chung

Blood (2024) 144 (Supplement 1): 347.

https://doi.org/10.1182/blood-2024-209425

Published: 2024

Journal Articles

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Blood (2024) 144 (Supplement 1): 4325.

https://doi.org/10.1182/blood-2024-202596

Published: 2024

Journal Articles

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

Blood (2024) 144 (Supplement 1): 4324.

https://doi.org/10.1182/blood-2024-211178

Published: 2024

Journal Articles

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Blood (2024) 144 (Supplement 1): 1008.

https://doi.org/10.1182/blood-2024-206538

Published: 2024

NARROW

Risk prediction for clonal cytopenia: multicenter real-world evidence

Association between Smoking Intensity, Genetic Mutations, and Disease Progression in Myelodysplastic Syndromes

R289, a Dual Irak 1/4 Inhibitor, in Patients with Relapsed/Refractory (R/R) Lower-Risk Myelodysplastic Syndrome (LR-MDS): Initial Results from a Phase 1b Study

Myelodysplastic Syndromes with Concomitant SF3B1 Mutation and Deletion of the Long Arm of Chromosome 5 ( SF3B1 del5q ): Outcomes and Response to Treatment

A Randomized Phase 2 Trial of 28-Day (Arm A) Versus 14-Day (Arm B) Schedule of Venetoclax + Azacitidine in Newly Diagnosed Acute Myeloid Leukemia Patients ≥ 60 Years

Ivosidenib in Patients with Mutant Isocitrate Dehydrogenase 1 (m IDH1 ) Relapsed/Refractory Myelodysplastic Syndromes: Update of the Phase 1 Substudy per the International Working Group 2023 Response Criteria

Genetic Profiling and Survival Analysis of Patients with Acute Myeloid Leukemia and a History of Autoimmune Disease

Clinical and Molecular Insights into the Classification Dilemma: Are MDS/AML Cases Distinct from Secondary AML?

Impact of Response to Hypomethylating Agent-Based Therapy on Survival Outcomes in the Context of Baseline Clinical-Molecular Risk and Transplant Status in Patients with Myelodysplastic Syndromes/Neoplasms (MDS): An Analysis from the International Consortium for MDS (icMDS) Validate Database

Results from a Phase 1 Open-Label Dose Escalation and Expansion Trial of Oral Azacitidine + Cedazuridine (ASTX030) in Patients with Myelodysplastic Syndromes (MDS) and MDS/Myeloproliferative Neoplasms (MPN)

Ziftomenib Combined with Intensive Induction (7+3) in Newly Diagnosed NPM1- m or KMT2A -r Acute Myeloid Leukemia: Interim Phase 1a Results from KOMET-007

Demographics, Characteristics, Survival and Outcomes in Older, Untreated, Acute Myeloid Leukemia Patients with NPM1 Mutations or KMT2A rearrangements from the Beat AML Master Clinical Trial

Effect of Prior Treatments on the Clinical Activity of Imetelstat in Transfusion-Dependent Patients with Erythropoiesis-Stimulating Agent, Relapsed or Refractory/Ineligible Lower-Risk Myelodysplastic Syndromes

A Phase 1, Open-Label, Dose Escalation and Dose Expansion, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Lomonitinib (ZE46-0134) in Adults with FLT3 -Mutated Relapsed or Refractory Acute Myeloid Leukemia

Correlation of Patient-Reported Outcomes with Red Blood Cell Transfusion Reduction and Rise in Hemoglobin in Patients with Lower-Risk Myelodysplastic Syndromes in the IMerge Trial

A Multicenter, Phase Ib/II Study That Combines Luspatercept and Lenalidomide (L2) in Lower-Risk, Non-Del(5q) Patients with Myelodysplastic Syndromes: Phase Ib Results

Bi-Allelic DDX41 Mutations Exert Stage Specific Effects on Hematopoiesis to Promote Disease

IDH2 Mutation Is Associated with Favorable Outcome Among Older Adults with Newly Diagnosed Acute Myeloid Leukemia Treated with Lower-Intensity Therapy

Outcomes and Survival in Newly Diagnosed, Older, Acute Myeloid Leukemia Patients from the Beat AML Master Trial in the Venetoclax/Azacitidine Age

IO-202, a Novel Anti-LILRB4 Antibody, with Azacitidine for Hypomethylating Agent-Naive Chronic Myelomonocytic Leukemia: Phase 1b Expansion Cohort Results

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only